Table 1. Patient baseline characteristics.
| N=21 | |
|---|---|
| Male/female, n (%) |
14 (67) / 7 (33) |
| Median age (range), years |
55 (41–69) |
|
Race, n (%) | |
| White | 16 (76) |
| Black | 2 (10) |
| Asian | 2 (10) |
| Hispanic |
1 (5) |
|
Primary tumour, n (%) | |
| Colorectal | 17 (81) |
| Gastric | 2 (10) |
| Gallbladder | 1 (5) |
| Oesophageal |
1 (5) |
|
ECOG PS, n (%) | |
| 0 | 7 (33) |
| 1 | 13 (62) |
| Not reported |
1 (5) |
|
Metastatic sites followed for 18FLT-PET analyses, n (%) | |
| Lung | 6 (29) |
| Liver | 5 (24) |
| Lymph node | 3 (14) |
| Abdominal wall | 2 (10) |
| Pelvis |
2 (10) |
|
Previous therapy, n (%) | |
| Surgery | 21 (100) |
| Chemotherapy | 16 (76) |
| 1 prior regimen | 1 (5) |
| 2 prior regimens | 4 (19) |
| 3 prior regimens | 4 (19) |
| >3 prior regimens | 7 (33) |
| Radiation | 9 (43) |
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; 18FLT-PET=fluorine-18 3′-deoxy-3′-fluorothymidine positron emission tomography.